Cardio Diagnostics Expands into India with Aimil, Lal PathLabs, Finalizes Medicare CPT and Payment Steps
CDIO•Cardio Diagnostics CEO Dr. Meesha Dogan outlined expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs and described completion of CPT coding and payment steps in the Medicare reimbursement process. Coverage determination is pending as the company leverages its AI-driven genetic-epigenetic engine for cardiovascular precision medicine.
1. CEO Outlines Precision Medicine Strategy
Dr. Meesha Dogan emphasized the use of an AI-driven integrated genetic-epigenetic engine to improve cardiovascular disease prevention, early detection and management, positioning the company at the forefront of precision medicine.
2. India Expansion Partnerships
Cardio Diagnostics has forged partnerships with Aimil Ltd. and Dr. Lal PathLabs to launch its proprietary cardiovascular diagnostic tests in India, leveraging established local distribution channels to accelerate market entry and adoption.
3. Medicare Reimbursement Progress
The company has secured CPT coding approval and finalized payment steps under Medicare, with coverage determination still pending, marking a key milestone toward broader U.S. reimbursement and potential revenue growth.
